Cancer & HBOT
Clinical studies reveal the benefit of HBOT in combating the effects and risk of cancer.
In 2013, over 1.6 million people were diagnosed with cancer and over 500,000 cancer-related deaths occurred in the U.S. alone. Cancer is one of the leading causes of death, world-wide, and new integrated treatments are being utilized to help combat its devastating effects. Hyperbaric oxygen therapy (HBOT) is currently being utilized in conjunction with conventional treatments, including radiation and chemotherapy, to attain optimal dosages for patients, stimulate tumor regression and reduce the side effects of treatments. Cancer thrives in hypoxic or low-oxygen environments and HBOT has been shown to increase these oxygen levels to weaken tumors and reduce their aggressiveness.
Studies have revealed the benefits of HBOT in the following areas:
- Conventional Cancer Treatments
- Side Effects of Conventional Cancer Treatments
- Tumor Aggression
- Natural Killer Cell Activity
- Cancer Prevention
HBOT has been shown to be benefitial in reducing the effects and risk of cancer. Some of those benefits include:
Conventional Treatment
- Reduces tumor hypoxia
- Better radiation therapy results
- Improves chemotherapy outcome
- Enhances glioblastoma treatment
- Decreases tumor drug resistance
- Allows for optimal therapy dosage to be attained
- Increases post-op fibroblast activation
Side Effects of Conventional Treatment
- Reduces radiation therapy side effects
- Accelerates post-operative healing & prevents infection
- Decreases chemotherapy side effects
- Reduces Chemo-Brain Syndrome symptoms
Tumor Aggression
- Weakens hypoxic tumors
- Targets metastatic tumors
Natural Killer Cell Activity
- Increases reactive oxygen species production
- Amplifies cancer cell death
- Regresses tumor volume
Cancer Prevention
- Decreases inflammatory markers
- Normalizes intracellular oxygen levels
- Stimulates cellular detoxification
- Reduces risk of pathogenic inflammatory-related tumors
- Supports cellular energy processes for optimal DNA repair
Study: HBOT Stimulates Tumor Regression
A non-randomized trial was conducted with 29 patients to evaluate the effectiveness of radiotherapy combined with HBOT in patients with a malignant tumor. Fifteen patients were irradiated daily after HBOT and fourteen other irradiated patients were treated without HBOT. In the HBOT group, 11 of 15 patients (73 percent) showed greater than 50 percent tumor regression. In the non-HBOT group, only four of 14 patients (29 percent) underwent tumor regression. The average survival rate in patients with HBOT doubled that of the non-HBOT group (24 months vs. 12 months) respectively. No serious side-effects were observed in the HBOT patients.
This provides additional support for HBOT to be a beneficial treatment for malignant tumors.